{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:43:43Z","timestamp":1793299423283,"version":"4.5.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41571-020-0414-y","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T14:04:46Z","timestamp":1594389886000},"page":"589-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Simultaneous development of zanubrutinib in the USA and China"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-7220","authenticated-orcid":false,"given":"Guanqiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-3444","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"414_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(17)30406-0","volume":"18","author":"M Wang","year":"2017","unstructured":"Wang, M. Clinical trials and drug approvals continue to accelerate in China. Lancet Oncol. 18, 855 (2017).","journal-title":"Lancet Oncol."},{"key":"414_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2017.10","volume":"14","author":"Q Zhou","year":"2017","unstructured":"Zhou, Q., Chen, X. Y., Yang, Z. M. & Wu, Y. L. The changing landscape of clinical trial and approval processes in China. Nat. Rev. Clin. Oncol. 14, 577\u2013583 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"414_CR3","unstructured":"National Medical Products Administration. National Medical Products Administration Approves Zanubrutinib http:\/\/www.nmpa.gov.cn\/WS04\/CL2056\/377969.html (2020)."},{"key":"414_CR4","unstructured":"U.S. Food and Drug Administration. Drug Approval Package: BRUKINSA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/213217Orig1s000TOC.cfm (2019)."},{"key":"414_CR5","unstructured":"Nasdaq Investors. BeiGene Announces the Approval of BRUKINSA\u2122 (Zanubrutinib) in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma http:\/\/ir.beigene.com\/news-releases\/news-release-details\/beigene-announces-approval-brukinsatm-zanubrutinib-china (2020)."},{"key":"414_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cpt.1180","volume":"104","author":"A Ramamoorthy","year":"2018","unstructured":"Ramamoorthy, A. et al. Demographic composition of select oncologic new molecular entities approved by the FDA between 2008 and 2017. Clin. Pharmacol. Ther. 104, 940\u2013948 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"414_CR7","unstructured":"The New York Times. The F.D.A. Is in Trouble. Here\u2019s How to Fix It https:\/\/www.nytimes.com\/2020\/01\/11\/opinion\/sunday\/fda-commissioner-stephen-hahn.html (2020)."},{"key":"414_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41587-019-0405-7","volume":"38","author":"C Morrison","year":"2020","unstructured":"Morrison, C. Fresh from the biotech pipeline-2019. Nat. Biotechnol. 38, 126\u2013131 (2020).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0414-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:47:52Z","timestamp":1733957272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0414-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1038\/s41571-020-0414-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"10 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}